Liraglutide biosimilar - Glenmark Pharmaceuticals
Alternative Names: LirafitLatest Information Update: 16 Feb 2024
At a glance
- Originator Glenmark Pharmaceuticals Ltd
- Class Anti-inflammatories; Antihyperglycaemics; Antiparkinsonians; Antirheumatics; Glucagon-like peptides; Obesity therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 2 diabetes mellitus
Most Recent Events
- 03 Jan 2024 Launched for Type 2 diabetes mellitus (In adults) in India (Unspecified route)
- 02 Jan 2024 Registered for Type 2 diabetes mellitus (In adults) in India (unspecified route) prior to January 2024
- 01 Jan 2024 Clinical trials for Type 2 diabetes mellitus (In adults) in India (Unspecified route) prior to January 2024